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Abstract 
Background: It has been shown that Carbohydrate antigen (CA) 125 and CA 19-9 
tumor markers are useful for diagnosis and follow up of ovarian carcinoma. 
Case: In this case, we reported the high level of CA-125 and CA 19-9 with large 
right ovarian intact endometrioma and extensive involvement of omentum. 
Conclusion: Human Epididymis protein (HE4) and Risk of ovarian malignancy 
algorithm (ROMA) can be useful in differentiation between malignancies and 
benign pathologies with a good sensitivity and specificity value. 
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Introduction 
 
umor markers has been shown are 
useful for diagnosis and follow up of 
treatment in patients with 
gynecological malignancies. Carbohydrate 
antigen (CA) 125 that is a type of cell surface 
glycoprotein, is the best-known tumor marker 
for ovarian carcinoma as it rises in more than 
80% of non-mucinous epithelial ovarian 
carcinomas (1). CA 19-9 is another tumor 
marker that rises in some ovarian masses 
although it commonly elevates in 
gastrointestinal and pancreatic malignancies 
(2-4). One of the most common benign 
diseases that are associated with the 
increased level of CA-125 is endometriosis (5-
7) but it rarely elevates more than 100 IU/ml in 
endometriotic patients (8). 
In cases of rupture of endometrioma, the 
serum concentration of CA-125 elevates as 
high as 10,000 IU/ml with varying amounts of 
ascites (1, 9) similar to those seen in ovarian 
malignancy, but in this case we reported the 
high level of CA-125 and CA 19-9 with large 
right ovarian intact endometrioma and 
extensive involvement of omentum. 
 
Case report 
 
An 18 year old virgin girl was referred to 
clinic of gynecology in a university tertiary 
hospital with constant low grade lower 
abdominal pain from 2 weeks ago. 
Dysmenorrhea, gastrointestinal, or urinary 
tract symptoms was negative. She had regular 
menstrual cycles and her body mass index 
was 26.6. Because of abdominal obesity, we 
couldn't touch any masses in abdominal 
exam.  
Since she was virgin, vaginal exam was 
refused and in rectal exam a large cystic mass 
with mild tenderness in the right side of pelvis 
was palpable. Abdominopelvic 
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Khodaverdi et al 
414                                        International Journal of Reproductive BioMedicine Vol. 16. No. 6. pp: 413-416, June 2018 
ultrasonography revealed 14×10 cm complex 
multiseptate cystic mass containing solid 
components in the right ovary and a little free 
fluid in the cul-de-sac. Right ovary and uterus 
were normal. These data were confirmed in 
abdominopelvic spiral CT scan with and 
without contrast. 
Complete laboratory tests including tumor 
markers requested. All laboratory tests were 
normal except Lactate dehydrogenase that 
was 253 (normal upper limit: 280 u/l). In tumor 
marker panel, alpha fetoprotein, β-HCG, 
carcinoemberionic antigen (CEA) were in 
normal range. The serum concentrations of 
CA-125 and cancer antigen 19-9 were 6484 
IU/Ml and 1309 IU/Ml (reference range 35 
IU/Ml). Human Epididymis protein 4 (HE4) 
was 50.7 and Risk of ovarian malignancy 
algorithm (ROMA) was 11%. CA-125 and CA 
19-9 were measured by using appropriate 
chemiluminescent immunoassay kits (ROSHE 
Company, ELECSYS 2010 devices).  
Although HE4 and ROMA were in low risk 
for malignancy, because of very high levels of 
other tumor markers, ovarian malignancies 
were in the top of the differential diagnosis yet 
and after achieving written consent about 
cancer surgery, laparotomy with midline 
incision was done. A unilateral 14×10 cm 
cystic mass with very fine adhesions of cyst 
on the right side of corpus of uteri was 
detected. There was no free fluid or seeding in 
peritoneal cavity and cul-de-sac was not 
obliterated.  
Abdominal organs had normal view but the 
omentum was covered with many diffuse 
small endometriotic foci (black puckered 
lesions). In spite of chocolate-like content of 
the cyst and almost certain diagnosis of 
endometriosis frozen section confirmed the 
diagnosis. Then ovarian cystectomy was done 
and the biopsy from peritoneum was taken. 
Histological examination approved the 
endometriosis of omentum and 
endometrioma. The serum level of the CA-125 
and CA19-9 decreased rapidly post  
operation. 
 
Ethical consideration 
The informed consent for reporting of the 
case was obtained from the patient. 
Discussion 
 
We reported an 18 year old girl with lower 
abdominal pain and extremely high levels of 
CA-125 (6484 IU/Ml) and CA19-9 (1309 
IU/Ml). The exact diagnosis was 
endometriosis. In the management of 
gynecologic patients, CA-125 and CA19-9 are 
used for differentiation between benign and 
malignant pathologies. In more than 80% of 
ovarian epithelial tumors, the serum 
concentration of CA-125 rises above 35 IU/ml 
(10) but it could be elevated in some 
physiologic states and benign conditions like 
menstruation and endometriosis. 
CA-125 is secreted from the human 
endometrium and its concentration in the 
content of endometrioma could be high up to 
1000,000 U/ml (11), although the 
concentration of CA-125 in patients with 
endometriosis rarely is more than 100 IU/ml 
(12). However, peritoneal mesothelial cells 
have more power than cancer cells in 
production of CA-125 (13). The important 
point in the interpretation of results is the 
magnitude of the elevation. It is reported that 
the serum levels of CA-125 >200 IU/ml are 
potentially associated with ovarian 
malignancies (14). 
CA19-9 is other high-molecular-weight 
glycoproteins that increase in endometriosis 
(8, 10). It is shown along with advanced 
stages of endometriosis, the mean serum 
levels of the CA19-9 increases (4). The 
presented case had stage-3 endometriosis 
according to American Society for 
Reproductive Medicine Revised Classification 
of Endometriosis (16). 
In this case, we had very high level of CA-
125 without malignancy. The patient had 
diffuse endometriosis patch on the omentum 
like the cases reported by Agha Hosseini et al 
(15). The common things between these two 
cases were unruptured ovarian endometrioma 
and black puckered lesions of endometriosis 
of the omentum. Our assumption is that 
involvement of omentum by endometriosis is 
the cause of such an exaggerated increase in 
the serum level of CA-125 and CA19-9 
without ovarian malignancy. Especially since 
CA-125 and CA19-9 in adnexal mass 
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the omentum has a very extensive surface, 
consequently there is very large amount of 
ectopic endometrium for secreting these 
tumor markers. 
In the literature every high levels of serum 
CA-125and/or CA19-9 in endometriosis as 
high as 9537 IU/ml and 15653 IU/ml are 
reported in a patient with ruptured ovarian 
endometrioma (1, 8, 17) but in our patient we 
had extraordinary levels of CA 125 and CA 
19-9: 6484 IU/Ml and 1309 IU/Ml with 
enraptured endometrioma. 
Other points that were observed in this 
case were the normality of the HE4 and 
ROMA despite every high level of CA-125 and 
CA19-9. Sensitivity of HE4 and CA-125 for 
discriminating ovarian cancer from benign 
pathologies was 86.2% and 93.1% for ROMA 
and the specificity was 87.4, 78.9 and 90.7 % 
for HE4, Ca-125 and ROMA (18). Since CA-
125 is a nonspecific tumor marker, it is shown 
that determination of HE4 while there is a high 
level of CA-125 levels could confirm the 
benign nature of ovarian endometrioma (19, 
20). 
 
Conclusion 
 
In conclusion, we may be faced with very 
high levels of CA-125 and CA19-9 in many 
advanced stages of endometriosis even 
without leakage or rupture of endometrioma. 
This happens particularly when the 
gastrointestinal organs or omentum is 
involved. As it has been shown in Ortiz-Muñoz 
et al study, in this situation HE4 and ROMA 
could be useful in differentiation between 
malignancies and benign pathologies with a 
good sensitivity and specificity value (18). 
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